Develops therapies for fibrosis and inflammatory diseases, focusing on modulating the immune response and tissue repair mechanisms.
FibroBiologics, Inc. is a pioneering cell therapy and regenerative medicine company dedicated to advancing treatments and potential cures for chronic diseases. Leveraging fibroblast cells and fibroblast-derived materials, the company is at the forefront of developing a robust pipeline aimed at addressing diverse medical conditions.
With a strong focus on innovation, FibroBiologics holds over 150 U.S. and international patents, with additional patents pending. These patents span various clinical pathways including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, organ involution reversal, and cancer treatment.
Founded in 2021 and headquartered in Houston, Texas, FibroBiologics is positioned at the intersection of cutting-edge research and therapeutic development. The company's commitment to pioneering regenerative therapies underscores its mission to significantly impact patient care and outcomes across a broad spectrum of chronic diseases.